Jana Lizrova Preiningerova
What Variability of Treatment Effect of Fampridine Can We Expect in People with Multiple Sclerosis?
Author(s): Klara Novotna, Jana Lizrova Preiningerova, Lukas Sobisek and Eva Kubala HavrdovaKlara Novotna, Jana Lizrova Preiningerova, Lukas Sobisek and Eva Kubala Havrdova
Background: Gait impairment represents one of the most common symptoms of multiple sclerosis (MS). Fampridine is the first symptomatic treatment aimed at improving gait. An objective measurement of the mobility improvement from treatment initiation has been recommended to evaluate treatment response. Objective: In this retrospective observational study, we evaluated what improvement in walking speed can be expected in people with multiple sclerosis (MS) treated with Fampridine in clinical practice, with respect to specific disability levels (EDSS 4.0-7.0). Methods: The mobility tests including the Timed 25 foot walk test (T25FW), Timed Up and Go test (TUG) and Step test (ST) were performed just before and 3 h after administration of Fampridine 10 mg tablet. Results: One hundred and thir.. Read More»